CompaniesAlliant Diagnostics

Alliant Diagnostics

defunct
About

Defunct Company

Areas of Focus

Categories

Rebranded/RenamedBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (2)
View all

Total Trials

2

As Lead Sponsor

1

As Collaborator

1

Total Enrollment

4,900

By Phase

PHASE4: 1

By Status

NOT_YET_RECRUITING: 1UNKNOWN: 1
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
NCT04860076
NCT06396858
Hover over trial bars to see details

Recent Trials

NCT06396858Collaborator
Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke
PHASE4Not yet recruiting
4,500 participants
Started: Jul 31, 2025 · Completed: Dec 31, 2026
NCT04860076Lead Sponsor
Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors
N/AUnknown
400 participants
Started: Jun 6, 2020 · Completed: Jun 6, 2023